Company intelligence / Profile preview

Graftys

Aix-en-Provence, Provence-Alpes-Côte d'Azur, Francegraftys.com ↗

Ownership: Private
Development stage: Other

Overview

Graftys has developed and commercialized synthetic calcium phosphate-based bone graft substitutes that are CE-marked and FDA-cleared. Over 80,000 units have been implanted worldwide. The company’s products are supported by more than a hundred scientific publications demonstrating safety and efficacy in orthopedic applications. No ongoing clinical trials reported; products are already marketed globally.

Therapeutic areas: NeurologyRheumatologyOther
Modalities: DeviceHydrogel-based drug delivery therapy (for combination products)Polymer-drug conjugate therapy (potentially for combination devices with pharmaceutical agents)Biologic (as bone graft substitutes mimic natural bone composition)
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Graftys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Graftys.

Explore the full profile